Clinical Trial Update: De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis [Phase 2]

View source ↗

Summary

Phase 2 study exploring de-escalated post-transplant cyclophosphamide (PTCy) combined with ruxolitinib for GVHD prophylaxis; the trial is currently active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Graft-versus-host Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING